## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.2% in mid entry zone (3.0-6.0%), top quartile (86th pct) cross-sectional ranking. Short-term MRS_5 (3.4%) confirms momentum alignment. Strong momentum (+7.6% 5-day acceleration). Outperforming sector by 3.7%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($37.61)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Arizona court weighs Centene bid to force provider case to arbitration**
- Source: Beinsure | 20251215T180951 | Somewhat-Bearish | Relevance: 100%
- The Superior Court of Arizona is considering whether a discrimination lawsuit filed against Centene Corp. should be moved to arbitration. Centene's affiliate, Arizona Complete Health, argues that their contracts with healthcare providers mandate arbitration for dispute resolution. The underlying lawsuit alleges that state agencies and insurers, including Centene, discriminated against healthcare providers serving Native American populations by targeting them in fraud investigations that allegedly lacked proper investigation and caused reputational damage.

**2. Centene Corporation $CNC Shares Acquired by Thrivent Financial for Lutherans**
- Source: MarketBeat | 20251214T132353 | Neutral | Relevance: 100%
- Thrivent Financial for Lutherans has significantly increased its stake in Centene Corporation, acquiring an additional 635,153 shares, bringing its total ownership to 1,814,059 shares valued at $98.47 million. Several other institutional investors also adjusted their positions in Centene during recent quarters. The company's stock currently holds a "Hold" rating from analysts with an average target price of $38.44.

**3. Bellevue Group AG Acquires 53,092 Shares of Centene Corporation $CNC**
- Source: MarketBeat | 20251213T090745 | Somewhat-Bullish | Relevance: 100%
- Bellevue Group AG increased its stake in Centene Corporation (NYSE:CNC) by 61.6% in Q2, acquiring an additional 53,092 shares to own a total of 139,310 shares valued at $7,562,000. Other hedge funds also adjusted their holdings in Centene, with institutional investors and hedge funds now owning 93.63% of the company's stock. Analysts currently rate Centene with a consensus "Hold" and a target price of $38.44.

**4. AQR Capital Management LLC Sells 2,750,812 Shares of Centene Corporation $CNC**
- Source: MarketBeat | 20251213T085300 | Neutral | Relevance: 100%
- AQR Capital Management LLC significantly reduced its stake in Centene Corporation ($CNC) by selling over 2.75 million shares, decreasing its holdings by 24.9% in the second quarter. Despite this, other institutional investors like Vanguard Group Inc., Norges Bank, and State Street Corp increased their positions in Centene. Analyst ratings for Centene are mixed, with a consensus "Hold" rating and an average target price of $38.44.

**5. National Bank of Canada FI Trims Stock Holdings in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251215T102419 | Neutral | Relevance: 63%
- National Bank of Canada FI reduced its stake in Elevance Health (NYSE:ELV) by 9.9% in Q2, selling nearly 20,000 shares but still holding 181,798 shares valued at approximately $70.7 million. Despite institutional investors owning 89.24% of the stock, analysts maintain a "Moderate Buy" rating with an average target price of $400.83. Elevance Health recently surpassed quarterly earnings estimates, reported strong revenue, and declared a $1.71 quarterly dividend.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Bernstein | $45 | $36 | +25% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Bernstein | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Long-term trend broken: trading 7.8% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +7.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.67 elevated, pricing in significant growth expectations. Forward P/E 14.0x attractive for 43% earnings growth. Balance sheet: $1.1B free cash flow. Analyst sentiment positive (1 raises, avg +25%). Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.9B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.67 |
| Forward P/E | 14.0 |
| Current P/E | 20.0 |
| YoY Growth | 43.0% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -2.4% to 5.2% (+7.6% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 86th percentile. MRS_5 at 3.4% confirms short-term momentum alignment. Outperforming sector by 3.7pp, stock-specific strength. Below SMA200 (0.92x), long-term trend not supportive. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.17% (CS: 86) | Strong |
| RSI_14 | 62.4 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 1.055x | Above |
| vs SMA50 | 1.096x | Above |
| vs SMA200 | 0.922x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $40.45
- **Stop Loss:** $37.61 (7.0% risk)
- **Target:** $44.71 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 422
- **Position Value:** $17,069.90
- **Portfolio %:** 17.07%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*